Use of Δ5-androstene-3β-ol-7,17-dione in the treatment of lupus erythematosus

• US 6,924,274 B2
• Filed: 05/08/2003
• Issued: 08/02/2005
• Est. Priority Date: 11/19/1997
• Status: Expired due to Fees

• Current Assignee: Interhealth Nutraceuticals Incorporated (Lonza Group AG)
• Original Assignee: Humanetic Corporation
• Inventors: Weeks, Charles E., Lardy, Henry A.
• Primary Examiner(s): Henley, III, Raymond J.
• Application Number:
  US10/431,960
• Publication Number:
  US 20040048839A1
• Time in Patent Office: 817 Days
• Field of Search: 514/169, 514/177, 514/178, 514/179, 514/182, 514/885
• US Class Current: 514/169
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders

Abstract

Lupus erythematosus can be treated by administering therapeutic amounts of Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof, such as Δ5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to Δ5-androstene-3β-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.

Claims

1. A method of treating an autoimmune disorder in a human having an autoimmune disorder, comprising administration to the human of a steroid selected from the group consisting of Δ

5-androstene-3β

-ol-7,17-dione and metabolizable precursors thereof incapable of being metabolized to androgens, estrogens or dehydroepiandrosterone, wherein said administration results in amelioration or prevention of one or more symptoms of said autoimmune disorder.

2. The method of claim 1, wherein said one or more symptoms are selected from the group consisting of lupus erythematosus-related arthritis, lupus erythematosus-related skin changes, lupus erythematosus-related hematologic abnormalities, lupus erythematosus-related kidney impairment, lupus erythematosus-related heart or lung disease, lupus erythematosus-related neuropsychiatric changes and lupus erythematosus-related tissue inflammation.

3. The method of claim 1, wherein said steroid is administered by the route selected from the group consisting of intravenous injection, mucosal administration, oral consumption, ocular administration, subcutaneous injection, and transdermal administration.

4. The method of claim 1, wherein said mucosal administration includes routes selected from the group consisting of buccal, endotrachael, inhalation, nasal, pharyngeal, rectal, sublingual and vaginal.

5. A method of treating a human having a disorder selected from the group consisting of discoid lupus, cutaneous lupus, drug-induced lupus and a systemic lupus disorder, comprising administration to the human of a steroid selected from the group consisting of Δ

5-androstene-3β

-ol-7,17-dione and Δ

5-androstene-3β

-acetoxy-ol-7,17-dione, wherein said administration results in amelioration or prevention of one or more symptoms of the disorder.

6. The method of claim 5, wherein said one or more symptoms are selected from the group consisting of lupus erythematosus-related arthritis, lupus erythematosus-related skin changes, lupus erythematosus-related hematologic abnormalities, lupus erythematosus-related kidney impairment or lupus nephritis, fever, joint pain or an arthralgia, arthritis, erythema, serositis, pleurisy, pericarditis, skin lesions, malaise, depigmentation, telangiectasia without scaring or atrophy, lupus erythematosus-related neuropsychiatric changes and lupus erythematosus-related tissue inflammation.

7. The method of claim 5, wherein said patient is a human and the systemic lupus is relapsing.

8. The method of claim 5, wherein said steroid is administered by the route selected from the group consisting of intravenous injection, mucosal administration, oral consumption, ocular administration, subcutaneous injection, and transdermal administration.

9. The method of claim 8, wherein said mucosal administration includes routes selected from the group consisting of buccal, endotrachael, inhalation, nasal, pharyngeal, rectal, sublingual and vaginal.